Marijuana Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Medical Marijuana, Inc. (MAJI) operates as a publicly traded, diversified hemp and cannabis products company focused on the development, manufacture, and distribution of hemp-derived CBD products and cannabis-related consumer goods. The company maintains an international footprint through its brand and distribution networks, spanning multiple regions and channels, and emphasizes scalable production, regulatory compliance, and brand development across its portfolio. Main products and services - Hemp-derived CBD products: CBD oil tinctures, capsules, topicals, and edible products produced under various brand lines; manufactured and distributed through e-commerce, direct sales, retail, and wholesale channels. - Consumer health and wellness products: Cannabinoid-based nutraceuticals and wellness items aligned with consumer trends in natural health. - Cannabinoid-based beauty and personal care: Hemp-derived topical and cosmetic preparations offered to retail and wholesale customers. - Cannabis drug and medication development: R&D and development services related to cannabis-based therapeutics, including formulation and potential pharmaceutical applications. - Supply chain and support services for the cannabis industry: Manufacturing, quality control, regulatory compliance, and logistics support for partner brands and distributors. - International market development: Market entry and expansion programs designed to establish regulatory-compliant CBD product access in new regions and countries. Geographic operations and structure - Headquarters and core operations are based in the United States, with international activity into Latin America and other regions via partnerships and regulatory-compliant distribution channels. - Operations span e-commerce platforms, wholesale networks, and direct selling arms to reach consumers globally. - Portfolio includes brands and subsidiaries focused on hemp-derived products and direct-to-consumer wellness offerings. Founding and corporate context - Founded in the early 2010s, with a stated headquarters in the United States, and a long-standing emphasis on pioneering in the cannabis and hemp sectors. - Maintains a diversified portfolio of brands and subsidiaries that collectively cover consumer health, beauty, and wellness segments linked to hemp CBD products. Latest major company changes - Strategic partnerships and alliances broaden market access for cannabis-related products and expand distribution networks in select international markets. - Product line expansions and new brand initiatives strengthen the company’s presence in hemp-derived consumer products, including wellness, beauty, and nutraceutical categories. - Organizational shifts and leadership updates enhance strategic focus on international expansion, regulatory compliance, and scalable manufacturing operations. - Acquisitions or investments in related cannabis and hemp ventures occur to augment capabilities in product development, formulation, and global distribution. - Launches of new product platforms and rebranding efforts aim to modernize the portfolio and improve market traction across channels. Additional context - Industry focus: Hemp-derived CBD products, consumer wellness, beauty, nutraceuticals, and cannabis-related therapeutic development. - Business segments: CBD consumer products (health, wellness, beauty), cannabis drug development, supply chain and manufacturing services, and international market development. - Target markets: Global consumer base through online channels, retail partners, and direct selling platforms; emphasis on Latin America and other regulated regions for CBD access and distribution. - Subsidiaries/parent relationships: Portfolio structure includes multiple operating brands and potential parent-subsidiary configurations that manage manufacturing, distribution, and brand development for hemp-based products.
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
Exousia Pro Reports Positive Outcome in Legal Proceeding
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
Exousia Pro Creates New Subdivisions
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
Exousia Pro Issues Update on Name Change
Exousia Pro Has Appointed Matthew Dwyer As Its New President
Exousia Pro Issues and Update on its FDA Orphan Drug Status
Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates